Proactive vaccination using multiviral Quartet Nanocages to elicit broad anti-coronavirus responses
- Creators
- Hills, Rory A.
- Tan, Tiong Kit
- Cohen, Alexander A.
- Keeffe, Jennifer R.
- Keeble, Anthony H.
- Gnanapragasam, Priyanthi N. P.
- Storm, Kaya N.
- Rorick, Annie V.
- West, Anthony P., Jr.
- Hill, Michelle L.
- Liu, Sai
- Gilbert-Jaramillo, Javier
- Afzal, Madeeha
- Napier, Amy
- Admans, Gabrielle
- James, William S.
- Bjorkman, Pamela J.1
- Townsend, Alain R.
- Howarth, Mark R.
Abstract
Defending against future pandemics requires vaccine platforms that protect across a range of related pathogens. Nanoscale patterning can be used to address this issue. Here, we produce quartets of linked receptor-binding domains (RBDs) from a panel of SARS-like betacoronaviruses, coupled to a computationally designed nanocage through SpyTag/SpyCatcher links. These Quartet Nanocages, possessing a branched morphology, induce a high level of neutralizing antibodies against several different coronaviruses, including against viruses not represented in the vaccine. Equivalent antibody responses are raised to RBDs close to the nanocage or at the tips of the nanoparticle’s branches. In animals primed with SARS-CoV-2 Spike, boost immunizations with Quartet Nanocages increase the strength and breadth of an otherwise narrow immune response. A Quartet Nanocage including the Omicron XBB.1.5 ‘Kraken’ RBD induced antibodies with binding to a broad range of sarbecoviruses, as well as neutralizing activity against this variant of concern. Quartet nanocages are a nanomedicine approach with potential to confer heterotypic protection against emergent zoonotic pathogens and facilitate proactive pandemic protection.
Copyright and License
© The Author(s) 2024. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Acknowledgement
We thank D. Staunton from the University of Oxford Department of Biochemistry Biophysical Suite for help with biophysical analysis. We thank the Centre for the AIDS Programme of Research in South Africa (CAPRISA) and G. Screaton (University of Oxford) for supplying SARS-CoV-2 variant isolates. The BtKY72 K493Y/T498W Spike plasmid for generating pseudovirus was a kind gift to the Bjorkman lab from D. Veesler (University of Washington). We thank the Cambridge Advanced Imaging Centre for TEM training and access to the microscopy facility. A.H.K. and M.R.H. disclose support for the research of this work from the Biotechnology and Biological Sciences Research Council (BBSRC grant no. BB/S007369/1). M.R.H. discloses support for the research of this work from the University of Oxford COVID-19 Research Response Fund and its donors (reference no. 0009517). R.A.H. discloses support for the research of this work from the Rhodes Trust. T.K.T. discloses support for the research of this work from the EPA Cephalosporin Early Career Teaching and Research Fellowship. R.A.H. and T.K.T. disclose support for the research of this work from the Townsend-Jeantet Prize Charitable Trust (Charity Number 1011770). G.A. discloses support for the research of this work from the University of Cambridge start-up funds. A.R.T. discloses support for the research of this work from the Chinese Academy of Medical Sciences (CAMS) Chinese Innovation Fund for Medical Science (CIFMS), China (grant no. 2018-I2M-2-002). P.J.B. discloses support for the research of this work from the National Institutes of Health (NIH grant no. AI165075), Caltech Merkin Institute and George Mason University Fast Grant.
Contributions
T.K.T. performed mouse immunizations. A.A.C., A.V.R. and A.P.W. performed and analysed yeast-display deep mutational scanning. J.R.K., P.N.P.G. and K.N.S. tested pseudovirus neutralization. W.S.J., M.L.H., S.L., J.G.-J., M.A. and A.N. tested virus neutralization. G.A. contributed to ELISAs. R.A.H. performed all other experiments. A.H.K. designed and purified initial Quartet constructs. R.A.H., T.K.T., A.A.C., W.S.J., P.J.B., A.R.T. and M.R.H. designed the project. R.A.H. and M.R.H. wrote the manuscript. All authors read and approved the manuscript.
Data Availability
Sequences of constructs are available in GenBank, as described in the section ‘Plasmids and cloning’. Plasmids encoding pDEST14-SpySwitch, pET28a-SpyCatcher003-mi3, pET28a-SpyTag-MBP, pcDNA3.1-SpyTag-SARS2 RBD Wuhan, pcDNA3.1-SpyTag-SARS2 RBD Delta, pcDNA3.1-SpyTag-SARS2 RBD BQ.1.1, pcDNA3.1-SpyTag-SARS2 RBD XBB.1.5, pcDNA3.1-SpyTag-Quartet, pcDNA3.1-Alternate Quartet, pcDNA3.1-Kraken Quartet, pcDNA3.1-Quartet [SARS1] and pcDNA3.1-SpyTag-Quartet_No_Linker have been deposited in the Addgene repository (https://www.addgene.org/Mark_Howarth/). Source data are provided with this paper. Requests for further information and/or resources and reagents should be directed to and will be fulfilled by the lead contact, M.R.H. (mh2186@cam.ac.uk).
Conflict of Interest
M.R.H. is an inventor on a patent on spontaneous amide bond formation (EP2534484) and a SpyBiotech co-founder and shareholder. M.R.H. and A.H.K. are inventors on a patent on SpyTag003:SpyCatcher003 (UK Intellectual Property Office 1706430.4). P.J.B. and A.A.C. are inventors on a US patent application filed by the California Institute of Technology that covers the methodology to generate cross-reactive antibodies using Mosaic nanoparticles. P.J.B. and A.A.C. are inventors on a US patent application filed by the California Institute of Technology that covers the monoclonal antibodies elicited by vaccination with Mosaic nanoparticles described in this work. P.J.B., A.A.C. and J.R.K. are inventors on a US patent application filed by the California Institute of Technology that covers the methods of isolating cross-reactive antibodies by vaccination with Mosaic nanoparticles. All other authors have no competing interests to declare.
Files
Name | Size | Download all |
---|---|---|
md5:85c9e7d3dbcb879b807477995bf60715
|
4.0 MB | Preview Download |
md5:30cfe9d441119673aef2c1c994c0c6de
|
109.1 kB | Preview Download |
md5:d4358bab03a2a92813345b8de80d0706
|
6.8 MB | Preview Download |
md5:d49b2b5e4e99e36fb68ee290737edc6b
|
25.9 kB | Download |
md5:e9e96537c3be21170dee56ed816b65e8
|
79.4 kB | Preview Download |
md5:63f74075ec8fc83ce04cdbfcc3313fcf
|
5.6 MB | Download |
md5:e534782528f2f9b576f3a7672a1544bd
|
40.7 kB | Download |
md5:46e32bf25f96664233a1c7e516a3968c
|
22.9 kB | Download |
md5:c4fc8b454dbe3dfc8f7c519754be21b1
|
17.3 kB | Download |
md5:5de03ab9e56ae9b265310e9c5f1643dc
|
58.6 kB | Preview Download |
Additional details
- ISSN
- 1748-3395
- Biotechnology and Biological Sciences Research Council
- BB/S007369/1
- Biotechnology and Biological Sciences Research Council
- BB/S007369/1
- University of Oxford
- University of Oxford COVID-19 Research Response Fund 0009517
- Rhodes Trust
- EPA Cephalosporin Early Career Teaching and Research Fellowship, Townsend-Jeantet Prize Charitable Trust
- Louis-Jeantet Foundation
- Townsend-Jeantet Prize Charitable Trust 1011770
- University of Cambridge
- Chinese Academy of Medical Sciences & Peking Union Medical College
- 2018-I2M-2-002
- National Institutes of Health
- AI165075
- California Institute of Technology
- Richard N. Merkin Institute for Translational Medicine
- George Mason University
- Caltech groups
- Division of Biology and Biological Engineering, Richard N. Merkin Institute for Translational Research